179 related articles for article (PubMed ID: 28590314)
21. Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications.
Rowe SP; Gorin MA; Pomper MG
Annu Rev Med; 2019 Jan; 70():461-477. PubMed ID: 30691373
[TBL] [Abstract][Full Text] [Related]
22. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.
Sheikhbahaei S; Afshar-Oromieh A; Eiber M; Solnes LB; Javadi MS; Ross AE; Pienta KJ; Allaf ME; Haberkorn U; Pomper MG; Gorin MA; Rowe SP
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2117-2136. PubMed ID: 28765998
[TBL] [Abstract][Full Text] [Related]
23. Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer.
Eder M; Schäfer M; Bauder-Wüst U; Haberkorn U; Eisenhut M; Kopka K
Prostate; 2014 May; 74(6):659-68. PubMed ID: 24464532
[TBL] [Abstract][Full Text] [Related]
24. PET imaging in urology: a rapidly growing successful collaboration.
Farolfi A; Koschel S; Murphy DG; Fanti S
Curr Opin Urol; 2020 Sep; 30(5):623-627. PubMed ID: 32701721
[TBL] [Abstract][Full Text] [Related]
25. Where to next prostate-specific membrane antigen PET imaging frontiers?
Donswijk ML; Morigi JJ; Little A; Vogel WV; van Leeuwen PJ
Curr Opin Urol; 2020 Sep; 30(5):672-678. PubMed ID: 32701718
[TBL] [Abstract][Full Text] [Related]
26. PET imaging of recurrent and metastatic prostate cancer with novel tracers.
Mertan FV; Lindenberg L; Choyke PL; Turkbey B
Future Oncol; 2016 Nov; 12(21):2463-2477. PubMed ID: 27527923
[TBL] [Abstract][Full Text] [Related]
27. Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker.
Huang SS; Wang X; Zhang Y; Doke A; DiFilippo FP; Heston WD
Prostate; 2014 May; 74(7):702-13. PubMed ID: 24615708
[TBL] [Abstract][Full Text] [Related]
28. Utility of
Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
[TBL] [Abstract][Full Text] [Related]
29. Clinical PET Imaging in Prostate Cancer.
Wallitt KL; Khan SR; Dubash S; Tam HH; Khan S; Barwick TD
Radiographics; 2017; 37(5):1512-1536. PubMed ID: 28800286
[TBL] [Abstract][Full Text] [Related]
30. Multimodality Imaging of Prostate Cancer.
Ghafoor S; Burger IA; Vargas AH
J Nucl Med; 2019 Oct; 60(10):1350-1358. PubMed ID: 31481573
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
32. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
[TBL] [Abstract][Full Text] [Related]
33. Will GRPR Compete with PSMA as a Target in Prostate Cancer?
Iagaru A
J Nucl Med; 2017 Dec; 58(12):1883-1884. PubMed ID: 28970333
[No Abstract] [Full Text] [Related]
34. Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer.
Liolios C; Schäfer M; Haberkorn U; Eder M; Kopka K
Bioconjug Chem; 2016 Mar; 27(3):737-51. PubMed ID: 26726823
[TBL] [Abstract][Full Text] [Related]
35. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
[TBL] [Abstract][Full Text] [Related]
36. Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging.
Hofman MS; Iravani A; Nzenza T; Murphy DG
Urol Clin North Am; 2018 Aug; 45(3):503-524. PubMed ID: 30031469
[TBL] [Abstract][Full Text] [Related]
37. Clinical impact of PET imaging in prostate cancer management.
Emmett L; Hruby G
Curr Opin Urol; 2020 Sep; 30(5):649-653. PubMed ID: 32732622
[TBL] [Abstract][Full Text] [Related]
38. The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory.
Sathianathen NJ; Geurts N; Nair R; Lawrentschuk N; Murphy DG; Lamb AD
Future Oncol; 2017 Aug; 13(20):1801-1807. PubMed ID: 28762288
[TBL] [Abstract][Full Text] [Related]
39. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer.
Foss CA; Mease RC; Fan H; Wang Y; Ravert HT; Dannals RF; Olszewski RT; Heston WD; Kozikowski AP; Pomper MG
Clin Cancer Res; 2005 Jun; 11(11):4022-8. PubMed ID: 15930336
[TBL] [Abstract][Full Text] [Related]
40. Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi.
Gorin MA; Marashdeh W; Ross AE; Allaf ME; Pienta KJ; Pomper MG; Rowe SP
Nucl Med Commun; 2017 Sep; 38(9):795-798. PubMed ID: 28704341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]